Beckley Psytech has reported positive Phase 2b clinical trial results for its intranasal psychedelic compound BPL-003 in patients with treatment-resistant depression. The trial demonstrated significant symptom reduction on the MADRS scale compared with a low-dose comparator, meeting primary and key secondary endpoints with 193 participants. This development contributes to the emerging class of psychedelic therapies gaining regulatory attention amid shifting political climates. Furthermore, Beckley advances its merger with Atai Life Sciences, consolidating efforts in this space.